Neon Therapeutics, Inc. Common Stock
NTGN
NTGN was delisted on the 5th of May, 2020.
52 hedge funds and large institutions have $127M invested in Neon Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 21 increasing their positions, 8 reducing their positions, and 4 closing their positions.
200% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 4
163% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 8
28% more capital invested
Capital invested by funds: $99.7M → $127M (+$27.6M)
18% more funds holding
Funds holding: 44 → 52 (+8)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.75M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$2.23M |
| 3 |
BlackRock
New York
|
+$1.98M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$833K |
| 5 |
JP Morgan Chase
New York
|
+$518K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.45M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.91M |
| 3 |
PIM
Partner Investment Management
San Francisco,
California
|
-$2.48M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$1.57M |
| 5 |
CC
Casdin Capital
New York
|
-$1.32M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CLOS
51
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| $1K | +$524 | +100 | New |
|
|
PCM
52
Prelude Capital Management
New York
| $1K | +$743 | +142 | New |
|
|
HA
53
HHLR Advisors
Grand Cayman,
Cayman Islands
| – | -$1.57M | -312,500 | Closed |
|
|
CC
54
Casdin Capital
New York
| – | -$1.32M | -263,344 | Closed |
|
55
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -107 | Closed |
|
NTGN Hedge Fund Activity: Q1 2019 in Review
52 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Neon Therapeutics, Inc. Common Stock (NTGN) for Q1 2019, worth a combined $127M — up 28% from $99.7M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new NTGN positions and 4 closed out — a net gain of 8 holders — while 21 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.75M. The largest seller was Wellington Management Group, cutting an estimated $3.45M.
- 52 institutional investors held Neon Therapeutics, Inc. Common Stock (NTGN) as of Q1 2019, up from 44 in Q4 2018.
- Funds reported $127M of Neon Therapeutics, Inc. Common Stock stock for Q1 2019, up 28% quarter-over-quarter.
- 12 funds opened new Neon Therapeutics, Inc. Common Stock positions in Q1 2019 and 4 closed out, a net change of +8 holders.
- The largest Neon Therapeutics, Inc. Common Stock buyer in Q1 2019 was Vanguard Group, an estimated $2.75M added.
- The largest Neon Therapeutics, Inc. Common Stock seller in Q1 2019 was Wellington Management Group, an estimated $3.45M sold.
Based on aggregated 13F filings for Q1 2019.